Biologics are the drugs derived from living tissue and interfere with body’s immune system to treat or prevent immune-mediated inflammatory responses. Their utility is mainly currently focused on some autoimmune disease such as Rheumatoid arthritis. Tofacitinib has been approved by FDA as first oral biologic for treatment of rheumatoid arthritis. It will be used in patients who don’t respond to to other immuno-suppressive therapies.
Progress in Oral Biologics for Rheumatoid Arthritis
Content is from proceedings of 2012 Annual European Congress of Rheumatology (EULAR).
Published in the journal of Oral Diseases (2012).
The FDA has given its seal of approval to Celgene Corporation’s Otezla, an oral treatment for psoriatic arthritis